23.07.2015 • News

Ardian Acquires ES and IM from DPx Holdings

Austrian private equity investor Ardian has acquired Exclusive Synthesis (ES) and Maleic Anhydride Intermediates & Specialties (IM) from Linz-based DPx Holdings for an undisclosed sum.

The assets held by the 51:49 joint venture of investor JLL Partners and Dutch chemical Group DSM were merged in 2013 from holdings of DSM Pharmaceutical Products and Patheon.

ES develops and produces chemical intermediates for agriculture and other industries. IM produces maleic anhydride, along with a large number of intermediates, derivatives and esters. Together they reported sales of some €200 million in 2014.

With Ardian’s support, management led by designated CEO Wolfgang Hillisch plans to “significantly strengthen” the units’ market position and expand through organic growth and acquisitions.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Top-Feature

most read